Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Tamoxifen compared with anastrozole for treatment of early breast cancer
September 29th, 2005
Tamoxifen was recently compared to anastrozole for treatment of early breast cancer. Tamoxifen, which is actually the gold standard adjuvant treatment in estrogen receptor-positive early breast cancer, is associated with an increased risk of endometrial cancer and other life-threatening events," according to recent research from Italy. "Moreover, many women relapse during or after tamoxifen therapy because of the development of resistance." "Therefore new approaches are required," stated F. Boccardo and colleagues. They "conducted a prospective randomized trial to test the efficacy of switching postmenopausal patients who were already receiving...
Source: Women's Health Weekly (2005-09-29)
|
